StockNews.com Initiates Coverage on InspireMD (NYSE:NSPR)

StockNews.com started coverage on shares of InspireMD (NYSE:NSPR) in a report published on Saturday. The firm issued a sell rating on the stock.

Separately, Lake Street Capital initiated coverage on shares of InspireMD in a research note on Wednesday, December 11th. They set a “buy” rating and a $5.00 price objective on the stock.

InspireMD Stock Up 16.0 %

Shares of InspireMD stock opened at $3.70 on Friday. The company has a market capitalization of $96.51 million, a price-to-earnings ratio of -4.93 and a beta of 1.00. InspireMD has a 12-month low of $1.81 and a 12-month high of $3.70. The firm’s 50-day moving average price is $2.80 and its two-hundred day moving average price is $2.74.

Institutional Investors Weigh In On InspireMD

A number of large investors have recently bought and sold shares of NSPR. Affiance Financial LLC lifted its holdings in shares of InspireMD by 2.9% in the fourth quarter. Affiance Financial LLC now owns 189,122 shares of the company’s stock worth $497,000 after acquiring an additional 5,376 shares during the last quarter. Parkman Healthcare Partners LLC bought a new position in shares of InspireMD in the third quarter worth about $279,000. Legato Capital Management LLC bought a new position in shares of InspireMD in the fourth quarter worth about $47,000. Northern Trust Corp lifted its holdings in shares of InspireMD by 103.7% in the fourth quarter. Northern Trust Corp now owns 48,022 shares of the company’s stock worth $126,000 after acquiring an additional 24,452 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC lifted its holdings in shares of InspireMD by 153.2% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 30,133 shares of the company’s stock worth $79,000 after acquiring an additional 18,233 shares during the last quarter. 44.78% of the stock is currently owned by institutional investors and hedge funds.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.